drugset

drugset / Trial / NCT07659379

Gotistobart Long Term Extension (LTE) Study

NCT07659379 ↗

Phase 3 Not yet recruiting 20 enrolled OncoC4, Inc.

Non-randomizedFactorialOpen-labelTreatment

Summary

This LTE study will examine the long-term overall survival and safety of gotistobart in patients with advanced solid tumors.

Timeline

Start: 2026-07-01
Primary completion: 2036-07-01
Completion: 2037-01-01

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	ONC-392	Monoclonal antibody	—	—

Indications